Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company. The medtech giant said the strategic decision can create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. The new company — […]
MassDevice Earnings Roundup
Embecta to undergo further restructuring, lowers guidance amid tariff impact
Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the discontinuation of its insulin patch pump program — the plan for which it says is substantially […]
Senseonics posts Q2 sales beat, submits 365-day CGM for CE mark
Senseonics (NYSE:SENS) shares dipped after hours today on first-quarter results that beat revenue projections on Wall Street. Shares of SENS fell 5% to 70¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $14.3 million. That equals 2¢ per share on sales of $6.26 million for the […]
Beta Bionics posts Q1 sales beat, raises 2025 guidance
Beta Bionics (Nasdaq:BBNX) shares remained unmoved after hours today on first-quarter results that topped the consensus sales forecast. Following its first-quarter performance, Beta Bionics increased its full-year guidance. After previously projecting between $80 million and $85 million in revenue, it now expects between $82 million and $87 million. The Irvine, California-based automated insulin delivery technology developer […]
Analysts are high on Dexcom after Q1 results, $750M repurchase program
Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus forecast. Shares of DXCM ticked up 3% to $72.30 apiece in post-market trading on Thursday. However, before hours on Friday, shares fell 1.6% to $70.26 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported profits of […]
Tandem stock rises after hours on Q1 sales beat
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after the market closed today on first-quarter results that beat the consensus forecast. Shares of TNDM ticked up 6.2% to $17.89 apiece in post-market trading today. The San Diego-based automated insulin delivery technology company reported losses of $130.56 million. That equals 1.97 per share on sales of […]
Beta Bionics posts Q4 sales beat to cap off ‘momentum-building year’
Beta Bionics (Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of BBNX ticked up nearly 2% to $15.50 apiece in poost-market trading today. This is the company’s first quarterly earnings report after it went public through a $234.6 million IPO in January. The Irvine, California-based automated insulin […]
Senseonics expects to double global patient base in 2025, progresses with pump integration
Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of SENS went up nearly 7% to 93¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $15.5 million for the quarter. That equals losses 2¢ per […]
Pump shipments increase by 25% in Q4 sales beat for Tandem
Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of TNDM fell 11% to $29.88 apiece in post-market trading today. The San Diego-based automated insulin delivery technology company reported profits of $755,000. That equals 1¢ per share on sales of $282.65 million for […]
Insulet sales increase 22% in 2024, Q4 performance beats Street
Insulet (Nasdaq:PODD) shares dipped after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of PODD fell 2.7% to $280.66 apiece in post-market trading on Thursday, Feb. 21. By midday trading on Friday, Feb. 22, shares were down 2.4%, at 281.36. The Acton, Massachusetts–based automated insulin delivery technology maker reported […]
